Rapavir

• Description :

  Rapavir (JH-B10) is a selective and potent sodium taurocholate cotransporting polypeptide (NTCP) inhibitor with an IC50 value of 1.8 nM for the uptake of taurocholic acid-d4 (TCA-d4) . Rapavir exerts antiviral activity by directly binding to NTCP and blocking the entry of the virus into cells during the HBV infection phase. Rapavir is promising for research of HBV infections[1].

• Product Name Alternative :

  JH-B10

• UNSPSC :

  12352101

• Target :

  HBV

• Related Pathways :

  Anti-infection

• Field of Research :

  Infection

• Smiles :

  O=C(COC1=CC([C@@H](CCC2=CC=C(C(OC)=C2)OC)OC([C@@H]3CCCCN3C4=O)=O)=CC=C1)N(C)CC(N[C@H](C(N([C@H](C(N[C@H](C(N(C)CC/C=C/C(OCC(C)(C4=O)C)=O)=O)CC5=CC=C(C=C5)F)=O)CC6=CC=CC=C6)C)=O)CC7=CC=C(C=C7)O)=O

• Molecular Formula :

  C68H79FN6O15

• Molecular Weight :

  1239.38

• References & Citations :

  [1]He J, et al. Rapavir, a novel inhibitor of sodium taurocholate cotransporting polypeptide, potently blocks hepatitis B virus entry. Signal Transduct Target Ther. 2025 Apr 23;10 (1) :130.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported